Unbiased Analysis of Today's Healthcare Issues
In the past, I have written about the Enhancing Oncology Model (EOM), including an overview of the EOM program as well as a more detailed review of EOM’s payment methodology. A new paper in JAMA Health Forum by Kocher and Adashi (2023) describes their perspective on the EOM program. First, they provide a nice overview…
Back in July, I provided an overview of the Enhancing Oncology Model (EOM). Today I build upon that post focusing largely on CMS’s EOM’s Payment Methodology. I use a Q&A format as well. What is the goal of EOM? According to CMS “EOM is a CMMI alternative payment model designed to advance health equity, promote…
The Yost Index is a measure of socioeconomic status (SES) across geographic areas. The index was developed by Kathleen Yost and coauthors in their 2001 paper titled “Socioeconomic status and breast cancer incidence in California for different race/ethnic groups.” There are seven key inputs to creating the Yost index were calculated at the Census block…
One would think that this question would be a relatively easy question to answer empirically: simply compare patients with delays against those without delays and see if there is a difference in health outcomes (e.g., survival). This approach, however, is problematic as due to three key methodological concerns. Measurement issues. Ideally, one would like to…
In part due to the COVID-19 pandemic, vaccination have become a hot button issue. This is true even for non-COVID vaccines that have proven significant health benefits, such as those for human papillomavirus vaccines (HPV). Although betweeen 2016 and 2021 the share of teenagers receiving their HPV vaccination series increased from 60% to 77%, Bloomberg…
FDA has two competing priorities. On the one hand, they want to collect as much data as possible to insure drugs are safe and effective; on the other hand, patients want access to innovative medicines as quickly as possible. To try to balance these priorities, FDA often will approve treatments based on evidence from surrogate…
The Oncology Care Model (OCM) is dead. The Oncology Care Model was a voluntary, alternative payment model (APM), that “included financial and performance accountability for episodes of care surrounding chemotherapy administration to cancer patients.” OCM expired at the end of June 2022, and will be replaced by the Enhancing Oncology Model. EOM is a also…
How do you measure changes in quality of life for patients with cancer? Today we will review 3 different approaches: health state based, health state with age decrements, and health state with time-to-death (TTD) decrements. Health state based. One common approach is just to use the quality of life of a given health state. For…
Cancer is the 2nd leading cause of death in the US, just behind heart failure. Yet in recent years, we have seen that improved prevention, screening and treatment has helped to avert 3.5 million deaths in the US over the past 3 decades. Despite these gains, we do see that cancer death rates are highly…
That is the title of my recent paper in Advances in Therapy along with co-authors Christian Jackisch, Federico Manevy, Suzanne Frank, and Nicki Roberts. This is a case study of the fixed-dose combination therapy of pertuzumab and trastuzumab as a subcutaneous injection compared to previous treatments which were administered via infusion. The abstract is below.…